Evolution Biotechnologies listed by OBN Ventures

Bedford, UK, July 20th 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has completed the registration process and has been listed on Oxford Business Network’s OBN Ventures Investment Platform at https://obn.envestry.com/.

Dr. David Harper, CEO of Evolution, said: “this is an important step forward in today’s difficult market, and we look forward to working with OBN Ventures to present this opportunity to a new group of investors”.

About OBN Ventures:

OBN Ventures Ltd (OBNV) is a wholly owned subsidiary of OBN (UK) Ltd, and offers a sophisticated FCA-approved on-line investment platform which is designed to bring a wide range of professional investors together with early-stage life sciences and related companies that in some instances are yet to achieve any revenues and in the majority of cases will not have reached the point of profitability. This platform is totally complementary in approach with OBN’s major investment conferences (BioTrinity® and BioSeed®) and offers the advantages of leveraging a wider range of investors and availability on a year-long basis. OBNV’s core strategy is to focus on early stage life sciences companies with strong intellectual property (‘IP’), and the potential for growth to £100m+ valuations or more, where the added value of OBNV/OBN may offer distinct advantage to investee companies.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email: pr@evolutionbiotech.com
Website: www.evolutionbiotech.com

Evolution Biotechnologies receives advance assurance for EIS status in the United Kingdom

Bedford, UK, June 8th 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has received advance assurance of eligibility for the Enterprise Investment Scheme (EIS) status from the tax authorities in the UK for its next investment round.

The EIS scheme provides additional tax relief for UK-based investors, and Evolution has secured EIS pre-approval for up to £3 million of investment.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution Biotechnologies is Working with Panda New Capital of Beijing to Access funding from the UK Government’s Future Fund

Bedford, UK, and Beijing, China – May 23rd 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, announced that on May 20th 2020, the UK Government launched an innovative new funding programme to support early-stage companies with a £250 million convertible loan matching fund, The Future Fund.

The Future Fund is open to companies that:

  • are incorporated in the UK;
  • have raised at least £250,000 in equity investment from third-party investors in the last 5 years
  • are not publicly listed
  • were incorporated on or before 31 December 2019; and
  • at least half of its employees are UK-based.

Evolution Biotechnologies is a privately held biotechnology business that was founded in the UK in 2015, and a majority of its employees are based in the UK.  Evolution is working with Panda New Capital to identify new investors to enable Evolution to access this important new funding stream for innovative UK companies.

Evolution Biotechnologies’ CEO, Dr David Harper said, “The Future Fund is a truly innovative way for the UK Government to support game-changing companies such as ours.  Accessing this funding with the support of new investors will enable Evolution to develop and commercialise its technology to benefit the thousands of people worldwide who suffer from asthma, who are deemed to be among the most vulnerable to novel respiratory infections such as COVID-19.”

Annie Han, President of Panda New Capital, said “The potential to have an investment matched by the UK Government should be very attractive for high quality investors from China seeking to support emerging companies such as Evolution Biotechnologies.  Having additional government funding supporting companies should enable them to achieve their objectives and build value more quickly.”

The Future Fund will match investments up to a maximum of £5 million.  Applications must be led by an investor, or group of investors who commit to invest a minimum of £125,000.  The investment structure is in the form of Convertible Loans which will work as follows:

1. The Government will loan between £125,000 and £5m over a maximum term of 36 months as long as this is matched by a private investor on a pound-for-pound basis.
2. The Loan will automatically convert into equity at a discount agreed with the investors that is at least a 20% discount rate to the next qualifying funding round. It will automatically convert into the most senior class of shares in the company.
3. If there is no qualifying round, it is up to the investors and the government whether to seek repayment with a 100% premium or to convert the loan into equity at a discount rate of at least 20%.

The UK government is committing at least £250 million in funding towards the scheme, which will initially be open until the end of September 2020. The funds will be provided on a first-come-first-served basis.

The UK Chancellor, Rishi Sunak, was quoted in the Financial Times on 18 May as saying that even though the Future Fund is initially capped at £250 million, he told MPs that he would be “more than happy” to expand the scheme if demand outstripped the money initially allocated.  He was further quoted to say, “These companies provide the growth of tomorrow and they deserve our full support.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution Biotechnologies receives Hong Kong patent for biological control of the house dust mite

Bedford, UK, April 3rd 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has received notice of award of Hong Kong patent number 1252537, “Acaricides”.

This patent protects the use of replicating biological agents for control of house dust mites, a key cause of asthma and other allergic conditions, and follows on from the award of European patent 3331366. Examination of applications proceeding from the underlying PCT application GB2016/052455 is proceeding in other jurisdictions.

Dr. David Harper, Evolution’s CEO, said “this represents a key part of our strategy and highlights the importance that we place on expanding our activities in Asian markets. This award represents further progress in protecting Evolution’s key technology, for the control of house dust mite infestations as a preventative for asthma. Asthma is of course of particular relevance during the current COVID-19 outbreak, where respiratory conditions are known to increase the risks of serious complications.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial targetis the development of a novel, self-amplifying biological control forthe house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution Biotechnologies announces the appointment of Panda New Capital of Beijing as global financial advisor to the company

Bedford, UK, March 18th 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports the appointment of Panda New Capital (PNC) and its partners as global financial advisors to the company.

Evolution has been working with Panda New Capital (PNC) since late 2019 and has agreed to expand the roles of PNC and its partner companies from Asian markets to a global role.

Dr. David Harper, Evolution’s CEO, said “we see expansion into Asia as a key priority for the company and we have found working with Panda New Capital to be highly productive. Based on results to date we are delighted to expand our involvement with PNC and look forward to working with them in wider global markets.”

Annie Han, President of Panda New Capital said “according to authoritative data, the import of asthma drugs and technology is an important direction. Evolution Biotechnologies’ patent as an international application of advanced biotechnology would fit well with the huge market demand in China.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial targetis the development of a novel, self-amplifying biological control forthe house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About Panda New Capital

Panda New Capital (PNC) is a global boutique investment firm, part of the new trend of Chinese capital. PNC has an accurate understanding of the Chinese economy and investment structures. It has a team with an extensive background in global capital markets on healthcare, energy and hightechnology. Since there is still a big gap between China and the world. The gap gives PNC a space to engage and share its investor resources, investment experiences and research capabilities. It’s strong and rich Chinese investor network is a great support for its foreign partners to reach objectives faster and more effectively.

Forward-looking statements

Panda New Capital (PNC) is a global boutique investment firm, part of the new trend of Chinese capital. PNC has an accurate understanding of the Chinese economy and investment structures. It has a team with an extensive background in global capital markets on healthcare, energy and hightechnology. Since there is still a big gap between China and the world. The gap gives PNC a space to engage and share its investor resources, investment experiences and research capabilities. It’s strong and rich Chinese investor network is a great support for its foreign partners to reach objectives faster and more effectively.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution receives letter of support from Asthma UK

Bedford, UK, June 7th, 2019

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today received a letter of support from Asthma UK, the charity dedicated to improving the health and well-being of the 5.4 million people in the UK whose lives are affected by asthma.

The letter was provided following a meeting with senior staff of the charity, and states: “Asthma UK welcomes your proposal, which seeks to establish a novel approach to remove triggers of asthma by targeting house dust mites through development of a biological control agent. People with asthma have more sensitive airways than people without asthma, which means they are more likely to react to triggers. Triggers are anything which sets off asthma symptoms, and people can have multiple triggers, ranging from cold viruses to pollen. House dust mites are a common problem for people with asthma, and in our Annual Asthma Survey 2018 64% of respondents stated that dust triggered their asthma symptoms.”

The letter goes on to say that: “Asthma UK appreciates that your proposal aims to find a novel way to rid the home of house dust mites, as this may be beneficial for people with asthma – removing possible problematic triggers and improving overall quality of life.”

Dr. David Harper, Evolution’s CEO, said: “It is extremely encouraging to receive such a statement of support from the leading charity dedicated to improving the lives of asthmatics in the UK.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document and the video interviewed referenced herein contain certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email: pr@evolutionbiotech.com
Website: www.evolutionbiotech.com

Evolution Biotechnologies selected to participate in InvestEU Matchmaking event 2019

Bedford, UK, February 23rd, 2019

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports that as a holder of the European Seal of Excellence for its work on house dust mite control, it has been selected to participate in the InvestEU Matchmaking event, to be held in Brussels, Belgium, on March 19th, 2019.

The event involves discussions on sustainable finance and innovation, the Investment Plan for Europe, the InvestEU programme, and the Horizon 2020 and Horizon Europe programmes. After the discussions, attendees are invited to attend a dedicated matchmaking session with a panel of 50 selected investors.

Dr. David Harper, Evolution’s CEO, said “this is an excellent opportunity to receive an update on these programs and to interact with an extensive group of interested investors. This builds on our receipt of the Seal of Excellence for our work on house dust mite control and on our recently allowed European patent protecting this work”.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document and the video interviewed referenced herein contain certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution CEO Dr. David Harper interviewed by Proactive Investors

Bedford, UK, January 9th, 2019

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports an interview with CEO Dr. David Harper, conducted by media company Proactive Investors during Biotech Showcase 2019.

The interview covered the background to Evolution’s development of a novel, self-replicating control technology for house dust mites. Also covered were the recent granting of a European patent for this approach, and the company’s development plans.

Dr. David Harper, Evolution’s CEO, said: “It is good to have the opportunity to speak to a wider audience about Evolution’s exciting developments in this novel area and the real and unmet need for this approach.”

The interview may be viewed here.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document and the video interviewed referenced herein contain certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

European Patent Office Notifies Intention To Grant for Evolution Biotechnology Patent EP3331366 “Acaricides”

Bedford, UK, January 9th, 2019

Evolution (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports the announcement by the European Patent Office of notification of intention to grant Evolution’s patent EP3331366, “Acaricides”.

The patent protects Evolution’s lead technology, developing a biological control for the house dust mite as a preventative for asthma.

The patent provides broad protection for any use of replicating biological agents for the control of house dust mites (HDM). The first claim protects “A method of treating or preventing a house dust mite infestation, said method comprising applying an acaricidal infectious agent at a site of a house dust mite infestation, or at a site proximal thereto, or at a site at risk of such infestation.”

As a result of this decision, Evolution now has exclusive control of the European market for this uniquely capable technology, with the potential to treat multiple mite habitats from a limited initial application. This market is projected to have potential for sales of more than $680M per annum in western Europe alone.

Grant in Europe is anticipated in the first half of 2019, with grant in Hong Kong following a quarter later. Corresponding applications are queued for examination in the USA, Australia, and Japan and will leverage our highly favourable PCT international examination report (IPRP).
Dr. David Harper, Evolution’s CEO, said “this is a huge step forward for the company, providing exclusivity for this uniquely capable approach in one of the largest markets in the world, with additional filings progressing in other areas.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution Biotechnologies announces presentation at Biotech Showcase, San Francisco, January 7th-9th, 2019

Bedford, UK, October 3rd 2018

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today announced its intention to present at the Biotech Showcase in San Francisco. CEO Dr. David Harper will present a summary of the company’s activities, along with news of a major development on its key asthma control technology.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com